Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Surgical Treatment of Atrioesophageal Fistula:A Systematic Review
Ann Thorac Surg 116:421-428, Amirkhosravi,F.,et al, 2023
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke
Stroke 53:1759-1763, Buckley, B.J.R.,et al, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020
Recurrent Cerebral Ischemia During Pregnancies
Neurol 95:e2453-e2457, Bulwa, Z.,et al, 2020
A 62-year-old man with history of catheter ablation presenting with recurrent strokes
Neurol 95:e3065-e3069, Jeanneret, V.,et al, 2020
Pregnancy, Hormonal Treatments for Infertility, Contraception, and Menopause in Women After Ischemic Stroke
Stroke 48:501-506, Caso, V.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Repeated Intravenous Thrombolysis for Early Recurrent Stroke
Stroke 47:2133-2135, Kahles, T.,et al, 2016
Early Start of DOAC after Ischemic Stroke
Neurol 87:1856-1862,1652, Seiffge, D.J.,et al, 2016
Recurrent Stroke in Childhood Cancer Survivors
Neurol 85:1056-1064, Fullerton, H.J.,et al, 2015
Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
NEJM 371:699-710, DeBaun, M.R.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
NEJM 367:817-825, The SPS3 Investigators, 2012
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurence
Stroke 42:2509-2514, Broderick, J.,et al, 2011
Effect of Combined Aspirin and Extended-Release Dipyridamole Versus Clopidogrel on Functional Outcome and Recurrence in Acute, Mild Ischemic Stroke: PRoFESS Subgroup Analysis
Stroke 41:732-738, Bath,P.M.W., et al, 2010
Aspirin and Extended-Release Dipyridamole Versus Clopidogrel for Recurrent Stroke
NEJM 359:1238-1251,1287, Sacco,R.L.,et al, 2008
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: No
Stroke 35:804-805,806, Tong,D.C. &Becker,K.J., 2004
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes
Stroke 35:803-804,806, Furlan,A.J., 2004
A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke
NEJM 345:1444-1451,1493, Mohr,J.P.,et al, 2001
Medical and Neurological Complications of Ischemic Stroke, Experience From the RANTTAS Trial
Stroke 29:447-453, Johnston,K.C.,et al, 1998
Nocturnal Blood Pressure Dip in Stroke Survivors, A Pilot Study
Stroke 26:1373-1378, Nakamura,K.,et al, 1995
Acute Anticoagulation Following Cardioembolic Stroke
Stroke 20:730-734, Rothrock,J.F.,et al, 1989
Results of the Seven-Year Prospective Study of Stroke Patients
Stroke 19:942-949, Scmidt,E.V.,et al, 1988
The Natural History of Lacunar Infarction:The Oxfordshire Community Stroke Project
Stroke 18:545-551, Bamford,J.,et al, 1987
Prevention of Recurrent Stroke
Jr. , et al, Stroke 12:731-73581., Leonberg,S.C., 1981